Aging Populations And Emerging Markets Will Transform Healthcare

Key Takeaways

• Aging populations and chronic diseases are set to boost demand, while innovation and minimally invasive procedures strengthen market position and expand revenues.
  
• Expansion in emerging markets and effective integration of acquisitions, together with digital health investment, are driving sustained growth and margin improvement.
  
• Prolonged regulatory delays, supply chain and tariff risks, and rising costs from pricing pressures and acquisitions threaten margins and could limit future revenue growth.

Catalysts

Operates as a medical technology company.

• Strong demand growth is expected to continue due to favorable demographics, with the aging global population and growing prevalence of chronic diseases fueling procedure volumes in orthopedics, hips, knees, trauma, and neurotechnology, leading to sustained revenue expansion.
  
• Significant international growth runway remains, especially as emerging markets in Asia-Pacific and Latin America expand healthcare infrastructure and as critical new products (like Insignia and Pangea) achieve regulatory approvals outside the US, supporting both near
• and long-term top-line growth.
  
• Robust innovation pipeline, particularly in robotic-assisted surgery (Mako platform) and next-generation devices, is driving greater market share, higher average selling prices, and service revenues, which is expected to accelerate both revenue and margin expansion over time.
  
• The ongoing industry shift to outpatient and minimally invasive procedures-where Stryker is a leading supplier of ASC infrastructure and advanced surgical solutions-positions the company to benefit from increased procedure volumes and deeper customer penetration, bolstering both revenue and operating leverage.
  
• Successful integration and expansion of recently acquired businesses (e.g., Inari Medical), combined with ongoing focus on operating efficiencies and digital health investments, should drive continued improvements in net margins and EPS growth beyond current expectations.

Stryker Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Stryker's revenue will grow by 8.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from 13.2% today to 20.0% in 3 years time.
• Analysts expect earnings to reach $6.5 billion (and earnings per share of $16.6) by about June 2029, up from $3.3 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $8.2 billion.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 28.6x on those 2029 earnings, down from 35.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.5x.
• Analysts expect the number of shares outstanding to grow by 0.28% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.69%, as per the Simply Wall St company report.

Risks

• Prolonged and unpredictable regulatory approval processes in Europe (EU MDR) have delayed key product launches (e.g., Pangea and Insignia not yet approved), which could constrain international revenue growth and increase R&D and compliance costs, ultimately impacting revenue and net margins.
  
• Heightened and persistent supply chain disruptions, especially in the Medical division, are causing ongoing product shortages and are expected to persist through year-end, which could limit sales growth and add cost pressure, negatively affecting revenue and potentially earnings in the near-to-medium term.
  
• Tariff risk remains significant, with $175 million in estimated impact for 2025, and while partially offset by pricing and operational efficiencies, future shifts in tariff policies or supply chain localization trends may increase costs and reduce profitability, pressuring net margins and earnings.
  
• Intensifying pricing and reimbursement pressures from government payers, especially in global markets like China (VBP policy) and countries with single-payer systems, may erode Stryker's pricing power and restrict top-line growth, directly affecting revenue and long-term earnings potential.
  
• Increased R&D, integration, and SG&A expenditures required for acquisition integration (e.g., Inari, NRE) and to maintain innovation leadership may compress net margins if not matched by sufficient revenue synergies, especially as Stryker absorbs salesforce turnover, onboarding challenges, and 'bad medicine' from restructuring acquired businesses.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $386.8 for Stryker based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $465.0, and the most bearish reporting a price target of just $315.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $32.6 billion, earnings will come to $6.5 billion, and it would be trading on a PE ratio of 28.6x, assuming you use a discount rate of 7.7%.
• Given the current share price of $312.2, the analyst price target of $386.8 is 19.3% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.